PMID- 21058202
OWN - NLM
STAT- MEDLINE
DCOM- 20110308
LR  - 20221207
IS  - 1532-7914 (Electronic)
IS  - 0163-5581 (Linking)
VI  - 62
IP  - 8
DP  - 2010
TI  - Curcumin and gemcitabine in patients with advanced pancreatic cancer.
PG  - 1137-41
LID - 10.1080/01635581.2010.513802 [doi]
AB  - Curcumin has a potent antiproliferative activity and can also potentiate the 
      antitumor effect of gemcitabine. This study was undertaken to evaluate the 
      activity and feasibility of gemcitabine in combination with curcumin in patients 
      with advanced pancreatic cancer. Seventeen patients were enrolled in the study 
      and received 8,000 mg of curcumin by mouth daily, concurrently with gemcitabine 
      1,000 mg/m(2) IV weekly x 3 of 4 wk; 5 patients (29%) discontinued curcumin after 
      a few days to 2 wk due to intractable abdominal fullness or pain, and the dose of 
      curcumin was reduced to 4,000 mg/day because of abdominal complaints in 2 other 
      patients. One of 11 evaluable patients (9%) had partial response, 4 (36%) had 
      stable disease, and 6 (55%) had tumor progression. Time to tumor progression was 
      1-12 mo (median 2(1/2)), and overall survival was 1-24 mo (median 5). Low compliance 
      for curcumin at a dose of 8,000 mg/day, when taken together with systemic 
      gemcitabine, may prevent the use of high doses of oral curcumin needed to achieve 
      systemic effect. Further studies should be conducted to evaluate the ability of 
      other formulations of curcumin to enhance the effect of chemotherapy in cancer 
      patients.
FAU - Epelbaum, Ron
AU  - Epelbaum R
AD  - Department of Oncology, Rambam Health Care Campus, Haifa, Israel. 
      epelbaum@rambam.health.gov.il
FAU - Schaffer, Moshe
AU  - Schaffer M
FAU - Vizel, Bella
AU  - Vizel B
FAU - Badmaev, Vladimir
AU  - Badmaev V
FAU - Bar-Sela, Gil
AU  - Bar-Sela G
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Nutr Cancer
JT  - Nutrition and cancer
JID - 7905040
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (bisdesmethoxycurcumin)
RN  - 0 (desmethoxycurcumin)
RN  - 0W860991D6 (Deoxycytidine)
RN  - IT942ZTH98 (Curcumin)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adenocarcinoma/drug therapy
MH  - Aged
MH  - Antimetabolites, Antineoplastic/administration & dosage/*therapeutic use
MH  - Antineoplastic Agents, Phytogenic/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Curcumin/administration & dosage/adverse effects/analogs & 
      derivatives/*therapeutic use
MH  - Deoxycytidine/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Disease Progression
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Medication Adherence
MH  - Middle Aged
MH  - Pancreatic Neoplasms/*drug therapy
MH  - Severity of Illness Index
MH  - Survival Analysis
MH  - Gemcitabine
EDAT- 2010/11/09 06:00
MHDA- 2011/03/09 06:00
CRDT- 2010/11/09 06:00
PHST- 2010/11/09 06:00 [entrez]
PHST- 2010/11/09 06:00 [pubmed]
PHST- 2011/03/09 06:00 [medline]
AID - 929165378 [pii]
AID - 10.1080/01635581.2010.513802 [doi]
PST - ppublish
SO  - Nutr Cancer. 2010;62(8):1137-41. doi: 10.1080/01635581.2010.513802.